Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases
- 18 April 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Medical Oncology
- Vol. 35 (5), 75
- https://doi.org/10.1007/s12032-018-1137-0
Abstract
To evaluate outcome in patients treated with stereotactic body radiotherapy (SBRT) on bone oligometastases from castration-sensitive prostate cancer after primary treatment. We retrospectively collected data of patients with less than five lesions at time of SBRT and hormone-naïve disease at the first extra-regional localization, treated between 03/2012 and 11/2016. Prostate-specific antigen (PSA) was measured every 3 months after SBRT. Imaging was performed in case of progression. Survival analysis was performed with Kaplan–Meier (log-rank test) approach. Fifty-five patients were treated on 77 bone oligometastases. Median age, initial PSA and pre-SBRT PSA were 72 years, 9.12 and 3.5 ng/mL, respectively. Twenty-five patients (45%) received SBRT alone while the remaining 30 patients (55%) received concomitant ADT. Median follow-up was 24.6 months (range 3.0–67.2 months). No acute or late toxicity of grade > 1 was reported. Clinical progression was observed in 38 (69%) patients. 1-year biochemical progression-free survival (b-PFS), clinical progression-free survival (c-PFS), prostate-specific survival (PCSS) and local control (LC) rates were 51, 56, 100 and 83%, respectively. Comparing patients treated with SBRT alone and with concomitant ADT, no significant differences were found for those outcomes. SBRT is safe and allows high 1-year LC rate (83%) with low toxicity profile. No significant improvement in outcomes was registered with the addition of ADT to SBRT.Keywords
This publication has 23 references indexed in Scilit:
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceRadiation Oncology, 2014
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2013
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013European Urology, 2013
- Stereotactic body radiotherapy for oligometastasesThe Lancet Oncology, 2013
- Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation TherapyClinical Genitourinary Cancer, 2012
- Oligometastases revisitedNature Reviews Clinical Oncology, 2011
- An Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation OncologySeminars in Radiation Oncology, 2008
- Modifying the American Society for Therapeutic Radiology and Oncology Definition of Biochemical Failure to Minimize the Influence of Backdating in Patients With Prostate Cancer Treated With 3-dimensional Conformal Radiation Therapy AloneJournal of Urology, 2003
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958